Announcements Trials
Browse Landscape

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Diabetes Mellitus, Type 2 2Pulmonary Disease, Chronic Obstructive 1Pancreatic Neoplasms 1Neoplasms 1Lung Neoplasms 1Disease 1

Interventions

pembrolizumab 1265Specimen Handling 926Magnetic Resonance Spectroscopy 830Carboplatin 823Cyclophosphamide 800Cisplatin 723Nivolumab 669Paclitaxel 627Radiotherapy 611Gemcitabine 573Biopsy 557Bevacizumab 478Dexamethasone 438fludarabine 407Docetaxel 380venetoclax 368Oxaliplatin 364Capecitabine 358Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 330Drug Therapy 326Doxorubicin 316Radiosurgery 315Standard of Care 309Blood Specimen Collection 308Pemetrexed 305Ipilimumab 299Radiation 286

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sulfonylurea Compounds × 1 year × Clear all
NCT07628556 2026-06-05

Antidiabetic Medications and Risk of Cancer

University of Pecs

Completed
74,799 enrolled

Diabetes Mellitus, Type 2, Neoplasms

NCT05663515 2026-06-02

EXCEED

AstraZeneca

Recruiting
24,000 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡